Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | CCR6 | P51684 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14464438 | 0.84 | FFAR4 (0.35) | — | |
| Hydrochloric Acid SCHEMBL819094 | 0.72 | MAPT (0.38) | ALDH1A1MAPTADRB1NPSR1 | |
| SCHEMBL22189038 | 0.67 | NPC1 (0.33) | MAPTHPGDADRB1NPSR1 | |
| Hydrochloric Acid SCHEMBL1697483 | 0.66 | MAPT (0.34) | ALDH1A1MAPTNPSR1 | |
| SCHEMBL4760153 | 0.63 | ALDH1A1 (0.40) | ALDH1A1MAPTHSP90AA1CCR6HPGD | |
| SCHEMBL20260122 | 0.61 | MAPT (0.50) | ALDH1A1MAPTHPGDADRB1NPSR1 | |
| Hydrochloric Acid SCHEMBL15329535 | 0.61 | RAB9A (0.31) | — | |
| SCHEMBL7729842 | 0.60 | MAPT (0.34) | ALDH1A1MAPTHSP90AA1CCR6HPGD | |
| Cyclohexane SCHEMBL1452174 | 0.59 | ALDH1A1 (0.53) | ALDH1A1MAPTHPGDNPSR1 | |
| Cyclopentane SCHEMBL29049188 | 0.59 | ALDH1A1 (0.53) | ALDH1A1MAPTHPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8361922-B2 | Organometallic ruthenium complexes and related methods for the preparation of tetra-substituted and other hindered olefins | MATERIA, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8361922-B2 | Organometallic ruthenium complexes and related methods for the preparation of tetra-substituted and other hindered olefins | MATERIA, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120123133-A1 | ORGANOMETALLIC RUTHENIUM COMPLEXES AND RELATED METHODS FOR THE PREPARATION OF TETRA-SUBSTITUTED AND OTHER HINDERED OLEFINS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2012-05-17 | — | — | US | disclosed |
| US-8008224-B2 | Organometallic ruthenium complexes and related methods for the preparation of tetra-substituted and other hindered olefins | MATERIA, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20070282148-A1 | Organometallic ruthenium complexes and related methods for the preparation of tetra-substituted and other hindered olefins | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2007-12-06 | — | — | US | disclosed |
| WO-2007075427-A1 | ORGANOMETALLIC RUTHENIUM COMPLEXES AND RELATED METHODS FOR THE PREPARATION OF TETRA-SUBSTITUTED AND OTHER HINDERED OLEFINS | MATERIA, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120123133-A1 | ORGANOMETALLIC RUTHENIUM COMPLEXES AND RELATED METHODS FOR THE PREPARATION OF TETRA-SUBSTITUTED AND OTHER HINDERED OLEFINS | ORC3, OXER1, CBR3 | ALDH1A1 2951/4885MAPT 2228/4885HSP90AA1 4607/4885 |
| US-20070282148-A1 | Organometallic ruthenium complexes and related methods for the preparation of tetra-substituted and other hindered olefins | ORC3, OXER1, CBR3 | ALDH1A1 2951/4885MAPT 2228/4885HSP90AA1 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.